Concord Biotech shares tumble 16% after weak Q3 earnings

Concord Biotech shares dropped 16% to Rs 1,777.7 on Friday after the company reported a 2.1% year-on-year (YoY) decline in consolidated net profit to Rs 75.92 crore in Q3 FY25, compared to Rs 77.57 crore in Q3 FY24.

Revenue from operations rose 1.4% YoY to Rs 244.22 crore in Q3 FY25, up from Rs 240.79 crore in the same quarter last year.

However, on a sequential basis, revenue declined 21.2% from Rs 310.18 crore in Q2 FY25, while net profit fell 20.7% from Rs 95.74 crore.


Total expenses for the quarter surged 7.2% YoY to Rs 159.6 crore, compared to Rs 148.9 crore in the year-ago period.

Also Read: Stocks in news: Vodafone Idea, RVNL, Glenmark, Hindalco, Religare Enterprises, RBL Bank

Concord Biotech shares target price

As per Trendlyne data, the average target price of the stock is Rs 2,171, indicating an upside of 15% from the current market price. The consensus recommendation from 5 analysts for the stock is a 'Buy'.

Concord Biotech technical indicators

Technically, the stock's relative strength index (RSI) is at 45.3. According to Trendlyne, an RSI below 30 is considered oversold, while above 70 indicates overbought conditions. Additionally, the MACD is above its center line but below the signal line.

The stock is trading below its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs).

Concord Biotech shareholding

As per the shareholding pattern available on Trendlyne, foreign institutional investors held an 8.3% stake in the company as of the December quarter of FY25, while the promoters hold 44.08%, and mutual funds have about a 4.86% stake.

Concord Biotech shares performance

At 10:31 am, the scrip was trading 11.4% lower at Rs 1,870 on the BSE. The stock has declined 12% year-to-date but gained 35% in the last 12 months. The company’s market capitalization stands at Rs 19,563 crore.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)